A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults
Latest Information Update: 10 Feb 2020
At a glance
- Drugs MRNA-1653 (Primary)
- Indications Metapneumovirus infections; Parainfluenza virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Moderna Therapeutics
- 05 Feb 2020 Status changed from active, no longer recruiting to completed.
- 06 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
- 02 Oct 2019 Interim results presented in the Moderna Therapeutics media release.